Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

FDA approves updated COVID-19 vaccines to better protect against current variants

Adapted vaccines from Pfizer/BioNTech and Moderna have been authorised for individuals aged six months and older

- PMLiVE

Incyte and Syndax’s Niktimvo granted FDA approval in chronic graft versus host disease

Approximately 42% of patients receiving an allogeneic stem cell transplant will develop the condition

- PMLiVE

New genomic technique could improve antibiotic-resistant bacteria tracking in hospitals

The sequencing method is able to track the spread of multiple bacteria at the same time

https://youtu.be/gwGFH9YhbLg

Time and Cost Savings with Virtual Medical Education – Perks of Virtual Medical Education

Step into the future of medical education with significant time and cost savings! Virtual learning allows healthcare professionals to engage in training without travel, cutting costs and conserving valuable work...

Impetus Digital

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug approved by MHRA but not recommended by NICE

The health technology assessment agency outlined that the drug's benefits are “too small” to justify its costs

- PMLiVE

J&J to expand cardiovascular capabilities with V-Wave acquisition worth up to $1.7bn

The company’s medtech division will gain access to a cardiovascular implant device for heart failure

- PMLiVE

FDA approves Galderma’s IL-31 inhibitor Nemluvio to treat prurigo nodularis in adults

The chronic skin condition is estimated to affect up to 181,000 people in the US

- PMLiVE

AstraZeneca’s Imfinzi/Lynparza regimens granted EC approval to treat endometrial cancer

Almost 125,000 new cases of endometrial cancer were diagnosed in Europe in 2022

- PMLiVE

Eli Lilly’s GIP/GLP-1 receptor agonist tirzepatide shown to significantly reduce type 2 diabetes risk

More than 5.6 million people in the UK are estimated to be living with a form of diabetes

- PMLiVE

J&J’s Rybrevant/Lazcluze combination approved by FDA as first-line lung cancer treatment

Non-small cell lung cancer accounts for up to 85% of all lung cancer cases

- PMLiVE

Measuring success: our key highlights from BrightonSEO

Attending BrightonSEO allows us to keep up to date with some of the latest developments and forward thinking in content marketing. It’s the biggest search marketing conference in the world,...

Wallace Health

- PMLiVE

Gilead’s Livdelzi receives FDA accelerated approval to treat primary biliary cholangitis

The company gained access to the drug through its $4.3bn acquisition of CymaBay in March

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links